-+ 0.00%
-+ 0.00%
-+ 0.00%
GlaxoSmithKline: The growth rate of R&D expenditure is expected to be significantly higher than the growth rate of sales in 2026.
Share
Listen to the news
GlaxoSmithKline: The growth rate of R&D expenditure is expected to be significantly higher than the growth rate of sales in 2026.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending